Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rezzonico, R.
Right arrow Articles by Dayer, J.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rezzonico, R.
Right arrow Articles by Dayer, J.-M.
Related Collections
Right arrow Signal Transduction
Right arrow Gene Expression
Right arrow Chemokines, Cytokines, and Interleukins
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, 15 May 2001, Vol. 97, No. 10, pp. 2932-2940

CHEMOKINES

Ligation of CD11b and CD11c beta 2 integrins by antibodies or soluble CD23 induces macrophage inflammatory protein 1alpha (MIP-1alpha ) and MIP-1beta production in primary human monocytes through a pathway dependent on nuclear factor-kappa B

Roger Rezzonico, Veronique Imbert, Rachel Chicheportiche, and Jean-Michel Dayer

From the Division of Immunology and Allergy, Clinical Immunology Unit (Hans Wilsdorf Laboratory), Department of Internal Medicine, University Hospital, Geneva, Switzerland; and INSERM U526, Faculté de Médecine, Nice, France.


    Abstract
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References

Chemokines and adhesion molecules such as integrins play a major part in the trafficking, extravasation, and recruitment of leukocytes to inflammatory sites. This study investigated the effects of beta 2 integrin engagement on chemokine production by freshly isolated human monocytes. We found that ligation of CD11b or CD11c but not CD11a alpha  chains of beta 2 integrins by antibodies or soluble CD23 (sCD23) fusion proteins rapidly induced transcription and secretion of interleukin 8, macrophage inflammatory protein (MIP) 1alpha , and MIP-1beta . Because the promoters of these chemokine genes contain kappa B binding sites, we assessed the possible role of nuclear factor-kappa B (NF-kappa B) in controlling induction of the genes through beta 2 integrin engagement. Electrophoretic mobility shift assays showed that sCD23 or antibodies to CD11b or to CD11c up-regulated DNA-binding activity of NF-kappa B. Activation of NF-kappa B was accompanied by degradation of its cytosolic inhibitor Ikappa B-alpha . Blockade of depletion of Ikappa B-alpha by proteasome inhibitors (proteasome inhibitor I or acetyl-leucinyl-leucinyl-norleucinal) led to concomitant inhibition of NF-kappa B DNA-binding activity and expression of MIP-1alpha and MIP-1beta messenger RNA induced by beta 2 integrin ligation. These results suggest that triggering of CD11b or CD11c beta 2 integrin on primary human monocytes provides activation signals leading to nuclear translocation of NF-kappa B and subsequent secretion of MIP-1alpha and MIP-1beta that may have an important role in recruitment of other inflammatory cells during initiation of an inflammatory response. (Blood. 2001;97:2932-2940)

© 2001 by The American Society of Hematology.

    Introduction
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References

Recruitment of circulating leukocytes to an inflammatory site in response to stimuli such as infectious agents (viruses, bacteria, and protozoans) or noninfectious processes (trauma, autoimmune disorders, and ischemia-reperfusion injury) is a crucial step in the development of both acute and chronic inflammatory responses. In all these conditions, extravasation of circulating leukocytes requires communication with vascular endothelial cells that in turn depends on an interrelated network of events involving the finely regulated action of inflammatory cytokines (ie, interleukin [IL] 1 and tumor necrosis factor [TNF]-alpha ), adhesion molecules (notably integrins), and chemoattractant cytokines called chemokines.

Chemokines are highly conserved, small, secreted or membrane-bound cytokines with molecular masses of 6 to 14 kd and a characteristic 4-cysteine motif in their amino acid sequence.1-3 Two main subfamilies are defined according to the position of the first 2 cysteine residues. In the CXC (or alpha -chemokine) subfamily, these residues are separated by one amino acid, whereas in the CC (or beta -chemokine) subfamily, they are adjacent. The beta -chemokines, which include monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein (MIP) 1alpha , MIP-1beta , and regulated on activation, normal T-cell expressed and secreted (RANTES) molecules, are potent chemotactic agents for monocytes.4,5 The migratory behavior of monocytes in response to a concentration gradient of these soluble chemotactic factors also depends on adhesion molecules, particularly the leukocyte-specific beta 2 integrins.

Integrins are part of a family of heterodimeric transmembrane glycoproteins that recognize a variety of ligands or counterreceptors, including extracellular matrix and cell-surface and plasma proteins, and that consequently control numerous physiologic functions, such as adhesion, locomotion, chemotaxis, and phagocytosis.6 Expression of beta 2 integrins is restricted to leukocytes, with distribution varying among leukocyte subtypes. The beta 2 integrins share a common beta  chain (CD18) and have at least 4 distinct alpha  chains noncovalently associated with CD18: lymphocyte functional antigen 1 (alpha Lbeta 2, CD11a/CD18), macrophage antigen 1 (Mac-1; alpha Mbeta 2, CR3, CD11b/CD18), p150,95 (alpha Xbeta 2, CR4, CD11c/CD18), and a newly characterized member, alpha Dbeta 2 (CD11d/CD18).7-9 Interestingly, some chemokines (MCP-1, MIP-1alpha , MIP-1beta , and RANTES) increase surface expression of CD11b/CD18 and CD11c/CD18 on human monocytes.10-12

The best characterized ligands of CD11a/CD18 are intracellular adhesion molecule (ICAM) 1 (CD54), ICAM-2 (CD102), and ICAM-3 (CD50), all of which are members of the immunoglobulin superfamily.13-17 CD11b/CD18 also binds to ICAM-1 and other soluble ligands, including fibrinogen, complement fragment iC3b, coagulation factor X, arginine-glycine-aspartic acid sequences, heparin-like glycosaminoglycans, certain forms of collagen, and bacterial lipopolysaccharide (LPS).18-25 The functional role and ligands of CD11c/CD18 have not been well defined but appear to be similar to those of Mac-1, ie, implicated in adhesion of monocytes to endothelium26 and binding to iC3b, fibrinogen, LPS, and type I collagen.27-30

Human CD23, the low-affinity receptor for IgE (Fcepsilon RII), is a 45-kd type II membrane glycoprotein expressed on many hematopoietic cell types, including B lymphocytes and monocytes. CD23 is cleaved into biologically active soluble fragments (sCD23), and this results in generation of a relatively stable 25-kd fragment.31 CD23 may be involved in a variety of IgE- or CD21-dependent biologic activities, such as cell-cell adhesion, B-cell survival in germinal centers, histamine release from basophils, and regulation of IgE production.32,33 It was also reported that CD23 is a functional ligand for CD11b and CD11c on human and murine monocytes.34-37

Although beta 2 integrins promote cellular adhesion in various immune-inflammatory processes, they also function like most transmembrane receptors that are capable of transmitting outside-in signals elicited by ligand binding and resulting in cellular effector responses. In monocytes, triggering of beta 2 integrins by monoclonal antibodies (mAbs) or sCD23 leads to production of nitric oxide and inflammatory cytokines (TNF-alpha , IL-1beta , and IL-6), induction of procoagulant activity, and up-regulation of cell-surface molecule expression.34,36-40 Such interactions could play a role in chronic inflammatory diseases, including systemic lupus erythematosus, inflammatory bowel disease, Sjögren syndrome, glomerulonephritis, and rheumatoid arthritis, in which increased levels of CD23 have been observed.35 However, little is known about the intracellular events regulating these cell functions. Therefore, we previously analyzed the signaling pathways leading to IL-1beta production with beta 2 integrin engagement on human monocytes.41

Because interaction of monocytes with endothelial cells results in chemokine production,42,43 we here investigated the mechanisms controlling production of MIP-1alpha and MIP-1beta (members of the CC chemokine subfamily) by primary human monocytes activated through CD11b or CD11c beta 2 integrin engagement.


    Materials and methods
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References

Reagents

RPMI 1640 medium, phosphate-buffered saline (PBS), penicillin, streptomycin, and L-glutamine were supplied by Life Technologies (Paisley, United Kingdom). Low-endotoxin fetal-calf serum (FCS) was from Seromed (Biochrom, Berlin, Germany). The Ficoll-Paque device was from Pharmacia (Uppsala, Sweden). Polymyxin B sulfate, neuraminidase, N-acetyl-leucinyl-leucinyl-norleucinal (ALLN), and all other chemicals were obtained from Sigma (St Louis, MO). The alpha -phosphorus 32 (32P) uridine triphosphate (1.115 GBq [3000 Ci] /mmol) was from Hartmann Analytic (Braunschweig, Germany). Proteasome inhibitor I (PSI) was obtained from Calbiochem (La Jolla, CA), human recombinant TNF-alpha from Biogen (Cambridge, MA), and soluble TNF receptor (sTNFR)-p55 from Amgen (Thousand Oaks, CA). Culture media contained less than 0.15 U/mL endotoxin on chromogenic Limulus amebocyte lysate assay.

mAbs and recombinant chimeric proteins

Anti-CD11a were from the Binding Site (Birmingham, United Kingdom; IgG1, clone BU17) and Pharmingen (San Diego, CA; IgG2b, clone G43-25B). Anti-CD11b were from R&D Systems (Minneapolis, MN; IgG1, clone 44) and Serotec (Oxford, United Kingdom; IgG1, clone ICRF44). Anti-CD11c were from the Binding Site (IgG1; clone BU15) and R&D Systems (IgG1, clone 3.9). The isotype mAb controls were from Pharmingen.

Human recombinant fusion proteins for sCD23 were the kind gift of Dr M. Bird (Glaxo Wellcome, Stevenage, United Kingdom). The human fusion protein ZZ-CD23 consists of the lectin domain of human CD23 linked to the protein A IgG binding domain (ZZ) and is produced in insect cells as described previously.44 ZZ-CD23 can form oligomers in solution. For these studies, we used polymeric ZZ-CD23 purified by gel filtration as described previously for mouse ZZ-CD23.36 ZZ-P selectin and ZZ-E selectin fusion proteins were used as negative controls in all experiments. MBP-CD23 chimeric protein consists of maltose binding protein fused to the C-terminal 25-kd form of human CD23. It was expressed in soluble form in Escherichia coli, purified by affinity chromatography on amylose resin, and processed to remove endotoxin by repeated passage through Detoxi-gel (Pierce, Rockford, IL).

Isolation of human monocytes

Monocytes from fresh peripheral blood of healthy volunteers were prepared as described previously.45 Briefly, peripheral blood mononuclear cells (PBMC) isolated by using a Ficoll density gradient were incubated at a concentration of 50 × 106 cells/mL in RPMI 1640 medium containing 10% heat-inactivated FCS for 40 minutes at 4°C, with rotation leading to monocyte aggregation. This was followed by 10 minutes of incubation on ice. Pellets of aggregated enriched monocytes were separated from nonaggregated PBMC by a gradient using FCS. Enriched monocyte preparations were further depleted of T cells and natural killer cells by rosetting with neuraminidase-treated sheep red blood cells. Final monocyte preparations routinely contained more than 90% CD14+ cells, less than 1% CD3+ cells, and less than 1% CD19+ cells. Cellular viability was greater than 90% on trypan blue exclusion. Polymyxin B (1 µg/mL) was present throughout the isolation procedure and during activation experiments to rule out contamination by low levels of endotoxin.46 Furthermore, to prevent activation on adhesion, monocytes were cultured and stimulated in polypropylene tubes unless indicated otherwise.

Monocyte activation and measurement of MIP-1alpha and MIP-1beta

Freshly isolated monocytes were cultured in flat-bottomed, 96-well tissue-culture trays (Corning Costar, Kennebunk, ME) at a concentration of 50 × 103 cells/well in complete RPMI medium in the presence of polymyxin B. Monocytes were cultured for various times in the presence of anti-beta 2 integrin mAbs or recombinant sCD23 fusion proteins. Culture supernatants were then tested for production of MIP-1alpha and MIP-1beta by enzyme-linked immunosorbent assays (ELISA; R&D Systems, Abingdon, United Kingdom). The limits of detection were 10 pg/mL and 4 pg/mL, respectively.

RNA extraction and RNase protection assays

Human monocytes (5-10 × 106 cells) were starved for 14 hours in RPMI 1640 medium supplemented with 1% FCS in polypropylene tubes (Falcon; Becton Dickinson, Heidelberg, Germany). Cells were harvested, resuspended in 500 µL RPMI and HEPES containing 1% FCS, and incubated in 2-mL tubes (Eppendorf, Germany) at 37°C with or without effectors. Total RNA was isolated by lysing the cells with Trizol reagent (Life Technologies) according to the manufacturer's instructions and analyzed for the level of expression of MIP-1alpha , MIP-1beta , IL-8, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) messenger RNA (mRNAs) by RiboQuant RNase protection assay (RPA) using the hck-5 multiprobe template set from Pharmingen. Briefly, riboprobes were labeled with 32P and hybridized overnight in solution with 1 to 2 µg RNA. The hybridized RNA was digested with RNase, and the remaining "RNase-protected" probes were purified, resolved on denaturating polyacrylamide gels, and imaged autoradiographically according to the RiboQuant protocol.

Western blot analysis

Nonadherent monocytes were starved for 14 hours in RPMI 1640 medium supplemented with 1% FCS in polypropylene tubes, and 7 × 106 cells were stimulated for various times in 2-mL polypropylene tubes at 37°C with or without effectors. After incubation, monocytes were washed twice with 1 mL ice-cold PBS and lysed in buffer A, which consisted of 50 mM HEPES (pH 7.5), 150 mM sodium chloride (NaCl), 0.8 mM magnesium chloride, 5 mM ethylene glycol tetraacetic acid (EGTA), 1% Nonidet P-40 (NP-40), 1 mM phenylmethyl sulfonyl fluoride (PMSF), 15 µg/mL leupeptin, 1 µM pepstatin, 1 mM sodium fluorescein (NaF), and 1 mM sodium orthovanadate (Na3VO4). The crude lysates were centrifuged at 15 000g for 20 minutes at 4°C, and protein concentrations in the supernatants were determined by using Bradford reagent (Bio-Rad, Hercules, CA). For Western blot analysis, total cell lysates (50 µg proteins) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to Hybond electrogenerated chemiluminescence (ECL) membrane (Amersham, United Kingdom). The blots were probed with anti-Ikappa B-alpha polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Secondary horseradish peroxidase-conjugated goat antirabbit antibody was supplied by Dako (Copenhagen, Denmark). Antibody-bound proteins were detected with the Amersham ECL system. Autoradiographic results were quantified by densitometric scanning on a laser densitometer equipped with ImageQuant software (Molecular Dynamics, Sunnyvale, CA).

Preparation of nuclear extracts and electrophoretic mobility shift assays

Nuclear extracts were prepared as described by Schreiber et al.47 Briefly, monocytes (10-15 × 106 cells) were lysed in 200 µL buffer A (10 mM HEPES [pH 7.9], 10 mM potassium chloride [KCl], 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol [DTT], 1 mM PMSF, 15 µg/mL leupeptin, 1 µM pepstatin, 1 mM NaF, and 1 mM Na3VO4) containing 0.6% NP-40. The lysates were centrifuged and nuclear proteins were extracted from pellets in buffer B (20 mM HEPES [pH 7.9], 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, and 1 mM DTT). The specific kappa B DNA probe (5'-AGTTGAGGGGACTTTCCCAGGC-3') was from Santa Cruz Biotechnology. Binding reactions were done with 5 µg nuclear proteins incubated for 25 minutes at 25°C with the radiolabeled kappa B probe (25 000 cpm) in 20 µL binding buffer (10 mM Tris [pH 7.5], 60 mM KCl, 1 mM EDTA, 10% glycerol, 1 mM DTT, and 1 mg/mL bovine serum albumin) in the presence of 100 ng poly dI-dC and 1 µg sonicated salmon-sperm DNA. DNA-protein complexes were separated on a 6% nondenaturing polyacrylamide gel in 0.5 × Tris-borate EDTA. When indicated, an excess of cold competitor oligonucleotides (kappa B or the unspecific nuclear factor [NF] 1 consensus binding site 5'-TTTTGGATTGAAGCCAATATGATAA-3') was preincubated for 15 minutes with nuclear extracts.


    Results
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References

Anti-CD11b and anti-CD11c mAbs and sCD23 fusion proteins are potent inducers of chemokine mRNA expression in human monocytes

We and others34,36,41,48 previously established that ligation of beta 2 integrins at the surface of human monocytes mediates outside-in signaling leading to synthesis and secretion of inflammatory cytokines, notably IL-1beta . Because monocytes are also an important source of chemokine production,49 we here investigated the effects of beta 2 integrin engagement on modulation of chemokine expression.

Enriched human monocytes (85%-90% CD14+ cells) were starved for 14 hours in medium supplemented with 1% FCS and then cultured under nonadherent conditions in polypropylene tubes for 15 minutes to 4 hours in the presence of either mAbs raised against CD11a, CD11b, or CD11c beta 2 integrin alpha  chains or sCD23 chimeric proteins. The concentrations used were those previously found to induce IL-1beta production.41 Cells were then analyzed for chemokine mRNA expression by RPA (Figure 1). We found that incubation of monocytes with anti-CD11b or anti-CD11c mAbs led rapidly to a marked induction of MIP-1alpha , MIP-1beta , and IL-8 mRNAs. These were detected after 30 minutes and maintained after 4 hours of activation. Similarly, stimulation of monocytes by 2 distinct sCD23 fusion proteins, MBP-CD23 and ZZ-CD23, through CD11b and CD11c counterreceptors, resulted in a potent increase in steady-state levels of MIP-1alpha , MIP-1beta , and IL-8 mRNAs. Interestingly, we did not observe induction of mRNAs of MCP-1 or interferon-gamma -inducible protein 10 (IP-10), 2 chemokines produced by monocytes under different activation conditions (data not shown). Furthermore, anti-CD11a mAbs and ZZ-P selectin chimeric protein had no effect on chemokine mRNA levels (Figure 1C and 1F), as was already reported for IL-1beta synthesis.41


View larger version (74K):
[in this window]
[in a new window]
 
Figure 1. Time course of MIP-1alpha and MIP-1beta mRNA induction by beta 2 integrin engagement. Nonadherent human monocytes (7 × 106 cells) were left untreated or stimulated for various times with the following effectors: anti-CD11b (ICRF44, 2 µg/mL; A) anti-CD11c (BU15, 2 µg/mL; B), anti-CD11a (BU17, 2 µg/mL; C) MBP-CD23 (1 µg/mL; D) ZZ-CD23 (1 µg/mL; E), and ZZ-P selectin (5 µg/mL; F). Cells were then harvested and total RNA was isolated and analyzed by RPA for expression of MIP-1alpha , MIP-1beta , IL-8, and GAPDH mRNAs. Results are representative of 2 distinct experiments.

The stimulatory effect of beta 2 integrin triggering on chemokine gene expression was dose dependent (Figure 2). Activation of monocytes by anti-CD11b or anti-CD11c mAbs stimulated MIP-1alpha , MIP-1beta , and IL-8 mRNAs at concentrations as low as 0.2 to 0.5 µg/mL and reached maximal levels at 5 to 10 µg/mL mAbs. Similarly, chemokine mRNAs were induced at a concentration of 0.1 µg/mL ZZ-CD23 or MBP-CD23 fusion proteins and maximal activation was reached with 2 to 5 µg/mL. These results constitute the first evidence that engagement of CD11b and CD11c is a potent and selective inducer of MIP-1alpha , MIP-1beta , and IL-8 mRNA expression in human monocytes.


View larger version (57K):
[in this window]
[in a new window]
 
Figure 2. Dose-dependent stimulatory effect of anti-CD11b and anti-CD11c mAbs and sCD23 chimeric proteins on the steady-state level of MIP-1alpha and MIP-1beta mRNAs. Monocytes (7 × 106 cells) were left untreated or incubated for 1 hour with various concentrations of the following effectors: anti-CD11b (ICRF44; A), anti-CD11c (BU15; B), ZZ-CD23 (C), and MBP-CD23 (D). RNA was isolated and analyzed for expression of MIP-1alpha , MIP-1beta , IL-8, and GAPDH mRNAs. Results are representative of 2 distinct experiments.

Ligation of CD11b and CD11c beta 2 integrins triggers MIP-1alpha and MIP-1beta release on human monocytes

In light of evidence that adhesion-dependent signaling can, under some circumstances, induce mRNAs without synthesis of the corresponding proteins by monocytes,50 we investigated the effects of beta 2 integrin triggering on MIP-1alpha and MIP-1beta secretion in our system (Figure 3). Freshly isolated human monocytes constitutively produced low levels of or no MIP-1alpha and MIP-1beta . However, after stimulation of monocytes by anti-CD11b mAbs, anti-CD11c mAbs, MBP-CD23, or ZZ-CD23 for 7 hours, release of high amounts of MIP-1alpha in culture supernatants was observed (6.27 ± 0.76 ng/mL, 14.05 ± 2.31 ng/mL, 5.15 ± 0.82 ng/mL, and 10.66 ± 1.85 ng/mL, respectively; Figure 3A). Under these conditions, MIP-1beta secretion was also markedly stimulated (3.32 ± 0.67 ng/mL, 8.22 ± 1.14 ng/mL, 2.55 ± 0.64 ng/mL, and 5.64 ± 0.2 ng/mL, respectively). Conversely, incubation with either IgG1 isotype control mAb, anti-CD11a mAbs, or ZZ-P selectin fusion protein had no effect on MIP-1alpha and MIP-1beta secretion, thereby confirming that the induction was not due to nonspecific activation through monocyte Fc receptors or mediated by the ZZ motif of CD23 fusion proteins. Evaluation of the time course of MIP-1alpha and MIP-1beta secretion with beta 2 integrin engagement showed that both chemokines were detected as early as 3 hours after stimulation and persisted for more than 24 hours (Figure 3B and data not shown). Furthermore, these data were consistent with the kinetics of induction of MIP-1alpha and MIP-1beta mRNAs (Figure 1).


View larger version (39K):
[in this window]
[in a new window]
 
Figure 3. Engagement of CD11b and CD11c by mAbs or sCD23 fusion proteins rapidly stimulates secretion of MIP-1alpha and MIP-1beta on freshly isolated human monocytes. (A) Human monocytes (50 × 103 cells/well) were incubated for 7 hours in medium alone or in the presence of the following antibodies or recombinant fusion proteins: isotype control IgG1 (5 µg/mL), anti-CD11a (clone BU17, 5 µg/mL), anti-CD11b (clone ICRF44, 20 µg/mL), anti-CD11c (clone BU15, 5 µg/mL), ZZ-CD23 and MBP-CD23 (0.5 µg/mL), and ZZ-P selectin (5 µg/mL). Secreted MIP-1alpha and MIP-1beta in the culture supernatants were detected by ELISA. Data are mean ± SE values (n = 3). Similar results were obtained with anti-CD11a (clone G43-25B), anti-CD11b (clone 44), and anti-CD11c (clone 3.9) mAbs (data not shown). (B) Monocytes were cultured for various times under the same conditions as the experiment depicted in panel A. Then, MIP-1alpha and MIP-1beta were detected in the culture supernatants by ELISA. Data are mean ± SD values from triplicate performance of one experiment representative of 2 others (for each condition, SD was < 5%).

Because monocytes are highly sensitive to endotoxin, we compared the effects of beta 2 integrin engagement by mAbs or sCD23 fusion proteins on chemokine expression in the presence and absence of polymyxin B (Figure 4A). Polymyxin B (10 µg/mL) had no effect on MIP-1alpha , MIP-1beta , and IL-8 mRNAs induced by anti-CD11b, anti-CD11c, or sCD23 chimeras, but it strongly blocked (70%-80% inhibition) expression of the chemokine transcripts induced by a large amount of LPS (200 ng/mL). Engagement of CD11b and CD11c on monocytes by mAbs or sCD23 was previously found to trigger release of TNF-alpha .34,37,48 Moreover, TNF-alpha is known to stimulate MIP-1alpha synthesis.51,52 To rule out the possibility that chemokine production was induced by beta 2 integrin triggering resulting from autocrine TNF-alpha production, we did experiments in the presence and absence of the TNF-alpha -blocking agent, sTNFR-p55 (Figure 4B). As expected, sTNFR-p55 totally blocked MIP-1alpha and MIP-1beta mRNA expression induced by soluble TNF-alpha , but it did not affect expression induced by anti-CD11 mAbs or sCD23 fusion proteins. Taken together, these results indicate that CD11b and CD11c beta 2 integrin ligation is a potent way to activate MIP-1alpha and MIP-1beta expression on human monocytes at both the mRNA and protein level. The findings also show that this chemokine production is not due to either endotoxin contamination or autocrine TNF-alpha production.


View larger version (44K):
[in this window]
[in a new window]
 
Figure 4. Effect of polymyxin B and sTNFR-p55 on induction of MIP-1alpha and MIP-1beta mRNAs. (A) Nonadherent human monocytes (7 × 106 cells) were left untreated or stimulated for 1 hour at 37°C with either anti-CD11b (5 µg/mL), anti-CD11c (5 µg/mL), LPS (200 ng/mL), ZZ-CD23 (1 µg/mL), or MBP-CD23 (1 µg/mL) in the presence or absence of polymyxin B (10 µg/mL). (B) Monocytes (7 × 106 cells) were left untreated or cultured for 1 hour at 37°C with anti-CD11a (5 µg/mL), anti-CD11b (5 µg/mL), anti-CD11c (5 µg/mL), MBP-CD23 (1 µg/mL), ZZ-CD23 (1 µg/mL), or soluble TNF-alpha (10 ng/mL) in the presence or absence of sTNFR-p55 (10-8 M). RNA was isolated and analyzed by RPA for expression of MIP-1alpha , MIP-1beta , IL-8, and GAPDH mRNAs. Results are representative of 2 distinct experiments.

Activation of NF-kappa B DNA-binding activity and degradation of Ikappa B-alpha in monocytes triggered by anti-CD11b and anti-CD11c mAbs or sCD23 chimeras

To gain insight into the molecular mechanisms by which beta 2 integrin engagement elicits induction of chemokines in monocytes, we investigated the NFs that could control MIP-1alpha and MIP-1beta mRNA transcription. MIP-1alpha and MIP-1beta promoters were cloned, characterized, and shown to contain kappa B response elements.53 Therefore, we concentrated on the DNA-binding activity of NF-kappa B with beta 2 integrin triggering on human monocytes (Figure 5). We performed electrophoretic mobility shift assays on nuclear extracts prepared from cells treated with anti-CD11b mAbs, anti-CD11c mAbs, or sCD23 chimeric proteins. Gel-shift studies using a consensus target sequence for NF-kappa B revealed a constitutive low level of DNA-binding activity in untreated nonadherent monocytes that was not altered during incubation with anti-CD11a mAbs or ZZ-P selectin. Interestingly, triggering of CD11b or CD11c by mAbs or sCD23 fusion proteins resulted in a significant increase in NF-kappa B DNA-binding activity after 30 to 60 minutes of activation (Figure 5A, lanes 4-7, and Figure 5B, lanes 2 and 4). The specificity of the protein-DNA complexes induced by beta 2 integrin engagement was confirmed by the finding that incubation with an excess (50-100 fold) of unlabeled kappa B oligonucleotide prevented ZZ-CD23-induced binding to the 32P-labeled kappa B probe (Figure 5B, lanes 5-6), whereas incubation with an NF-1 oligonucleotide did not (lane 7).


View larger version (27K):
[in this window]
[in a new window]
 
Figure 5. Engagement of beta 2 integrins at the monocyte cell surface stimulates NF-kappa B DNA-binding activity. (A) Nonadherent monocytes were left untreated (lane 1) or stimulated for 30 and 60 minutes with anti-CD11a (BU17, 5 µg/mL; lanes 2 and 3), anti-CD11b (ICRF44, 5 µg/mL; lanes 4 and 5), or anti-CD11c (BU15, 5 µg/mL; lanes 6, 7) mAbs. Nuclear extracts were prepared and NF-kappa B DNA-binding activity was assessed in bandshift experiments. Lane 8 shows the migration of the radiolabeled kappa B probe in the absence of nuclear extracts. (B) Nonadherent monocytes were incubated for 30 minutes with medium alone (lane 1), MBP-CD23 (2 µg/mL; lane 2), ZZ-P selectin (5 µg/mL; lane 3), or ZZ-CD23 (5 µg/mL; lane 4). NF-kappa B DNA-binding activity was measured in 5 µg nuclear extracts in bandshift experiments. The specificity of the DNA-binding complex was analyzed by incubation with a 50- and 100-fold excess of unlabeled kappa B probe (lanes 5 and 6) or a 100-fold excess of NF-1 oligonucleotide (lane 7) under the conditions depicted in lane 4. Results are the most representative of 4 distinct experiments.

The mechanism underlying NF-kappa B activation is known. It involves stimulus-induced serine phosphorylation, ubiquitination, and subsequent proteolysis of NF-kappa B inhibitory proteins (Ikappa B) by the proteasome complex, leading to activation and nuclear translocation of the transcription factor.54-57 Thus, we analyzed expression of Ikappa B-alpha protein in the cytosol of monocytes after beta 2 integrin ligation. As shown in Figure 6A and 6B, the level of Ikappa B-alpha decreased rapidly after 15 and 30 minutes of activation with anti-CD11b and anti-CD11c mAbs, respectively, and then increased again, probably because of Ikappa B-alpha neosynthesis. Similarly, the MBP-CD23 chimera induced a rapid and transient depletion of Ikappa B-alpha (Figure 6C). Moreover, the Ikappa B-alpha down-regulation appeared more sustained in cells treated with ZZ-CD23 fusion protein, probably because the concentration used was higher than that of MBP-CD23 (5 µg/mL versus 1 µg/mL). In contrast, Ikappa B-alpha remained stable after 30 minutes of stimulation with 10 µg/mL of either anti-CD11a mAbs or ZZ-P selectin fusion protein (data not shown). Because NF-kappa B up-regulates transcription of its own inhibitor,58 we next preincubated monocytes with cycloheximide to prevent new Ikappa B-alpha synthesis. Under these conditions, depletion of Ikappa B-alpha induced by anti-CD11b and anti-CD11c mAbs or sCD23 fusion proteins was more pronounced and prolonged.


View larger version (41K):
[in this window]
[in a new window]
 
Figure 6. Ligation of beta 2 integrins induces Ikappa B-alpha degradation. Nonadherent monocytes were preincubated for 30 minutes with or without 10 µg/mL cycloheximide and then stimulated for various times with anti-CD11b mAb (10 µg/mL; A), anti-CD11c mAb (10 µg/mL; B), MBP-CD23 (1 µg/mL; C) or ZZ-CD23 (5 µg/mL; D). Whole-cell extracts were prepared and 50 µg protein was separated on 10% SDS-PAGE and transferred to nitrocellulose membranes. Ikappa B-alpha proteins were revealed with anti-Ikappa B-alpha polyclonal serum followed by an ECL reaction. Diagrams represent the densitometric scanning of Ikappa B-alpha protein levels in each Western blot. Results are representative of 2 experiments.

Proteasome inhibitors prevent NF-kappa B activation mediated by beta 2 integrin ligation

Inhibitors of the proteasome complex block Ikappa B degradation and are therefore potent NF-kappa B inhibitors.59,60 However, proteolysis-independent pathways for NF-kappa B activation have also been observed.61 Therefore, we investigated whether 2 proteasome inhibitors, PSI and ALLN, would affect NF-kappa B activation induced by beta 2 integrin engagement. We found that preincubation of monocytes with PSI, a specific inhibitor of 20S proteasome chymotrypsin-like activity, abolished NF-kappa B DNA-binding activity induced by either anti-CD11b and anti-CD11c mAbs or sCD23 fusion proteins (Figure 7A). Similarly, ALLN significantly inhibited NF-kappa B activation by anti-CD11b and anti-CD11c mAbs in a dose-dependent manner, (Figure 7B), and NF-kappa B mobilization mediated by sCD23 chimeras was markedly suppressed by the maximal dose of ALLN (100 µM; Figure 7C).


View larger version (43K):
[in this window]
[in a new window]
 
Figure 7. Effect of proteasome inhibitors on NF-kappa B activation induced by beta 2 integrin triggering. (A) Nonadherent monocytes (10-15 × 106 cells) were not preincubated (lanes 1, 2, 4, 6, 8, 9) or were preincubated with 100 µM PSI for 1 hour (lanes 3, 5, 7, and 10) and then stimulated with medium alone (lanes 1 and 8), anti-CD11b mAb (10 µg/mL; lanes 2 and 3), anti-CD11c mAb (10 µg/mL; lanes 4 and 5), ZZ-CD23 (5 µg/mL; lanes 6 and 7), or MBP-CD23 (2 µg/mL; lanes 9 and 10) for 30 minutes. (B) Nonadherent monocytes were pretreated with increasing amounts of ALLN (2, 20, and 100 µM) for 1 hour (lanes 3-5 and 8-10) and then stimulated with mAbs to CD11b (10 µg/mL) or CD11c (10 µg/mL) for 30 minutes. (C) Nonadherent monocytes were incubated for 1 hour without ALLN (lanes 1, 2, 4, and 5) or with 100 µM ALLN (lanes 3 and 6) before stimulation for 30 minutes with ZZ-CD23 (5 µg/mL; lanes 2 and 3), MBP-CD23 (2 µg/mL; lanes 5 and 6), or medium alone (lanes 1 and 4). Nuclear extracts were prepared and analyzed for NF-kappa B DNA-binding activity in bandshift experiments. Results are representative of 3 similar experiments.

NF-kappa B activation is a prerequisite for CD11b and CD11c signaling of MIP-1alpha and MIP-1beta expression in monocytes

To determine the role of the NF-kappa B pathway in controlling MIP-1alpha and MIP-1beta up-regulation induced by CD11b or CD11c triggering, we assessed the effects of proteasome inhibitors on expression of chemokine transcripts (Figure 8). Preincubation of monocytes with 40 µM PSI abrogated or strongly decreased expression of MIP-1alpha and MIP-1beta induced by anti-CD11b and anti-CD11c mAbs or sCD23 fusion proteins (Figure 8A, 8C, and 8D). At the highest concentration used (100 µM), ALLN markedly inhibited MIP-1alpha and MIP-1beta gene expression on beta 2 integrin engagement (Figure 8B, 8C, and 8D). Both PSI and ALLN appeared to be more effective in blocking induction of steady-state mRNA levels of MIP-1beta than those of MIP-1alpha . The constitutive level of GAPDH mRNA was not altered under these conditions. Interestingly, IL-8 mRNA was not inhibited by PSI or ALLN; instead, it tended to be potentiated by them. Taken together, these results indicate that activation of NF-kappa B is mandatory for up-regulation of MIP-1beta gene expression and, to a lesser extent, MIP-1alpha gene expression with CD11b and CD11c beta 2 integrin engagement.


View larger version (53K):
[in this window]
[in a new window]
 
Figure 8. Effect of proteasome inhibitors on steady-state levels of MIP-1alpha , MIP-1beta , and IL-8 mRNAs induced by anti-CD11b/c mAbs or sCD23 fusion proteins. (A) Nonadherent monocytes (7 × 106 cells) were not preincubated or were preincubated with 40 µM PSI for 1 hour and then stimulated for 30 minutes with medium alone, anti-CD11a (5 µg/mL), anti-CD11b (5 µg/mL), or anti-CD11c (5 µg/mL) mAbs. (B) Cells were pretreated with increasing amounts of ALLN (2, 20, and 100 µM) for 1 hour and then stimulated with anti-CD11b (5 µg/mL) or anti-CD11c (5 µg/mL) mAbs for 30 minutes. (C,D) Monocytes were not preincubated or were preincubated for 1 hour with 40 µM PSI or 100 µM ALLN before stimulation for 30 minutes with ZZ-CD23 (2 µg/mL), MBP-CD23 (1 µg/mL), or medium alone. Total RNAs were isolated and analyzed by RPA. Results are representative of 3 similar experiments.


    Discussion
Top
Abstract
Introduction
Materials and methods
Results
Discussion
References

Numerous proinflammatory and anti-inflammatory genes, as well as genes not known to be related to immunity, are likely to be regulated in response to engagement of integrins. Growing evidence supports the idea that in addition to their crucial function in cell-adhesion reactions during immune-inflammatory mechanisms, beta 2 integrins also generate outside-in cellular signaling that leads to cell activation. We demonstrated previously that triggering of CD11b or CD11c alpha  chains of beta 2 integrins by mAbs or chimeric sCD23 on freshly isolated human monocytes rapidly activates signaling pathways of extracellular signal-regulated kinases 1 and 2 and p38-stress-activated protein kinase 2 that cooperate in controlling IL-1beta production.41 Our current results provide new evidence that CD11b and CD11c engagement can also have a profound effect on chemokine release and consequently on recruitment of inflammatory cells during initiation of an inflammatory response.

Many studies have established that chemokines not only induce leukocyte migration but that they also facilitate leukocyte adhesion, particularly through their stimulatory effect on cell-surface expression and avidity of both CD11b and CD11c but not CD11a.10-12,62,63 Conversely, interaction of monocytes with endothelial cells, platelets, or fibroblasts was reported to increase production of chemokines, particularly MIP-1alpha .43,64-67 However, the identity of the adhesion molecules expressed on monocytes and responsible for contact-induced chemokine secretion has not been determined.

In the current study, we found that direct triggering of CD11b and CD11c but not CD11a alpha  chains of beta 2 integrins on primary human monocytes stimulated synthesis of IL-8, MIP-1alpha , and MIP-1beta . IL-8 production was previously reported to be enhanced through beta 2 integrin aggregation on human polymorphonuclear neutrophils.68 The current study is the first to show that ligation of CD11b or CD11c by mAbs up-regulates MIP-1alpha and MIP-1beta expression and secretion on primary human monocytes. Our findings also indicate that the stimulation of MIP-1alpha and MIP-1beta production by anti-CD11b and anti-CD11c mAbs is physiologically relevant, since such stimulation can also be produced by the natural ligand of these integrins, sCD23. The induction probably takes place at the transcriptional level according to the rapid time course of induction of MIP-1alpha and MIP-1beta mRNA. Interestingly, the chemokine production induced by CD11b or CD11c ligation was selective for MIP-1alpha , MIP-1beta , and IL-8, since it did not take place on several other CC or CXC chemokines, including MCP-1, RANTES, and IP-10. As in our study of IL-1beta production,41 we can here rule out the possibility that endotoxin contamination contributed to activation of expression of the MIPs, since addition of polymyxin B sulfate, which binds to and neutralizes LPS,46 did not reduce the stimulatory activities of anti-CD11b and anti-CD11c mAbs or sCD23 fusion proteins but did markedly block the effect of 200 ng/mL LPS.

Proinflammatory cytokines, particularly IL-1beta and TNF-alpha , are potent inducers of in vitro and in vivo MIP-1alpha production on several cell types, including peripheral blood monocytes, alveolar macrophages, inflammatory fibroblasts, and osteosarcoma cells.51,52,64,69 Furthermore, we and others34,38,39,41,70-72 found that engagement of beta 2 integrins by different methods, including binding to specific mAbs, adherence to surface coated with fibrinogen, incubation with sCD23, and direct contact with T cells, plays an important role in the production of IL-1beta and TNF-alpha on monocytes. However, using sTNFR or IL-1Ra (data not shown), we showed that, in our system, expression of MIP-1alpha , MIP-1beta , and IL-8 induced by engagement of CD11b or CD11c was not mediated by prior secretion of TNF-alpha or IL-1beta .

In monocytes, induction of genes expressing inflammatory mediators such as adhesion molecules, cytokines, and chemokines is regulated partly by members of the NF-kappa B-Rel family of transcription factors. Furthermore, NF-kappa B was reported to control transcription of MIP-1alpha and IL-8.53,73 Thus, the aim of our study was to assess the role of the transcription factor NF-kappa B in the control of MIP-1alpha , MIP-1beta , and IL-8 expression in response to ligation of beta 2 integrins on primary human monocytes. We demonstrated for the first time that specific engagement by mAbs of CD11b or CD11c but not CD11a on nonadherent human monocytes induced nuclear translocation of NF-kappa B. These results are in agreement with previous studies showing that fibrinogen activates NF-kappa B transcription by signaling through CD11b-CD18 in U937 monocytic leukemia cells.74 To our knowledge, our study is the first to show that stimulation of human monocytes by sCD23 leads to activation of NF-kappa B.

In addition, using the proteasome-specific inhibitors PSI and ALLN to block NF-